QUADRACEL Drug Profile

Summary for Tradename: QUADRACEL

High Confidence Patents:	9
Applicants:	1
BLAs:	1

Pharmacology for QUADRACEL

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine Inactivated Poliovirus Vaccine
Chemical Structure	Diphtheria Toxoid Pertussis Vaccine Poliovirus Vaccines Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for QUADRACEL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for QUADRACEL Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Limited	QUADRACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125525	4,500,639	2002-09-29	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	QUADRACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125525	4,687,738	2006-06-16	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	QUADRACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125525	4,784,589	2007-01-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for QUADRACEL Derived from Patent Text Search

No patents found based on company disclosures

International Patents for QUADRACEL

Country	Patent Number	Estimated Expiration
New Zealand	591925
Canada	2741396
New Zealand	601345

Market Dynamics and Financial Trajectory for QUADRACEL

Last updated: April 12, 2026

What is the market position of QUADRACEL?

QUADRACEL is a combination vaccine used mainly for immunization against diphtheria, tetanus, pertussis, and poliomyelitis. It is a combination of Td (tetanus and diphtheria toxoids) and IPV (inactivated poliovirus vaccine). Produced by Sanofi Pasteur, it competes within the pediatric and adult vaccine markets. Despite being approved in multiple countries, its commercial success remains modest relative to other combination vaccines, such as Pediarix and Boostrix.

How does the regulatory landscape influence market access?

The vaccine holds approvals in the U.S., Europe, and several other regions, with certifications aligned under international standards (e.g., WHO prequalification). Regulatory pathways in the U.S., such as FDA licensure under the biologics license application (BLA), require rigorous clinical trial data demonstrating safety, efficacy, and manufacturing consistency. Some markets favor monovalent vaccines or alternative combination products, affecting demand.

In the U.S., the Vaccine for Children (VFC) program and private insurance coverage substantially influence vaccination rates. Supply chain stability and pricing policies, particularly in emerging markets, impact distribution and sales.

What are the key market drivers and barriers?

Drivers

• Global Immunization Goals: WHO’s Expanded Program on Immunization (EPI) emphasizes coverage of diphtheria, tetanus, polio, and pertussis, increasing demand for combination vaccines.
• Pandemic Influence: COVID-19 spotlighted vaccine infrastructure, though no direct effect on QUADRACEL’s market, increased awareness about immunizations may boost acceptance.
• Regulatory Approvals: Expansion into new markets through WHO prequalification and regulatory submissions can increase sales.

Barriers

• Vaccine Hesitancy: Public skepticism limits immunization rates, especially for multi-component vaccines.
• Competition: Other combination vaccines—such as Pediarix (DTP-IPV-Hep B)—capture significant market share. The absence of a pediatric indication for QUADRACEL in some regions restricts its usage.
• Pricing and Reimbursement: Cost constraints in low- and middle-income countries can restrict access, especially where government procurement dominates.

What is the current financial outlook?

Revenue and Sales Performance

• Historical Sales: Sanofi reports limited revenue contribution for QUADRACEL, with estimates suggesting annual sales below $50 million globally.
• Market Share: Within the combination vaccine segment, QUADRACEL accounts for less than 10% in key markets like the U.S. and Europe, primarily due to competition and limited indications.

Cost Structure and Profit Margins

• Manufacturing Costs: Economies of scale are limited, given the niche market. Complex manufacturing processes for inactivated viruses lead to higher costs.
• Pricing Strategies: Premium pricing exists in developed markets, considering regulatory costs, but aggressive pricing in emerging markets is constrained by reimbursement policies.

Revenue Growth Potential

• Expansion Opportunities: Regulatory approvals for adult booster indications could expand the market, especially in counties emphasizing adult immunizations.
• Pricing and Market Penetration: If marketed effectively as part of mass immunization campaigns, revenue could improve marginally, but market headwinds from vaccine competition persist.

How do competitive and macroeconomic factors affect financial trajectories?

Competitive Landscape

• Pediarix dominates the pediatric quadrivalent vaccine market in the U.S. and Europe, with higher sales volumes. It combines more antigens, appealing for comprehensive immunization schedules.
• Boostrix targets adolescent and adult Tdap markets, indirectly affecting QUADRACEL's adult booster share.
• Rising prominence of mRNA and other innovative platforms in the vaccine sector does not directly threaten QUADRACEL but affects overall R&D investment priorities in Sanofi.

Macroeconomic Factors

• Government budgets for immunization programs dominate vaccine procurement. Budgetary constraints in emerging economies restrict growth.
• International health initiatives, such as GAVI, influence vaccine price negotiations and purchase volumes in low-income countries.

What is the outlook for future investments?

Sanofi is unlikely to significantly increase investment in QUADRACEL unless it secures new indications or markets. Focus remains on broader portfolio segments with higher growth potential, such as mRNA vaccines or combination products with broader antigen coverage.

Key Takeaways

• QUADRACEL holds a niche position with limited market share.
• Its revenue trajectory depends on expanding indications, competitive dynamics, and regulatory approvals.
• Pricing remains constrained by market segment and reimbursement policies.
• Competition from broader combination vaccines limits growth potential.
• Opportunities exist in adult booster markets and emerging markets where immunization coverage expands.

FAQs

1. What are the main competitors of QUADRACEL? Pediarix (DTP-IPV-Hep B), Boostrix (Tdap), and other monovalent vaccines.

2. Can QUADRACEL expand into adult markets? Possible if approved for adult booster indications; regulatory pathways are feasible but not yet realized.

3. How does vaccine hesitancy impact sales? Hesitancy reduces overall immunization rates, limiting market size for all combination vaccines, including QUADRACEL.

4. Does new technology threaten QUADRACEL? Advances in protein-based and mRNA vaccines shift R&D focus away from traditional inactivated virus vaccines but do not directly threaten QUADRACEL without indications expansion.

5. What is the potential for market growth in low-income countries? Limited currently due to pricing, supply chain, and regulatory barriers, but growth could occur through international funding and partnerships.

---

References

[1] Sanofi Pasteur. (2022). Quadracel vaccine information.
[2] World Health Organization. (2021). Immunization schedule guidelines.
[3] GAVI. (2022). Vaccine procurement and funding reports.
[4] U.S. Food and Drug Administration. (2020). Vaccine licensing and approval.
[5] MarketWatch. (2023). Global vaccine market analysis.